CVM - AMEX

CEL-SCI Corporation

CVM·AMEX

$7.17

-6.5%

HealthcareBiotechnology

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$49.27M

EPS-13.5000

P/E Ratio-2.82

Earnings Date01/12/2026

26.99M

Assets

-12%

3Y-64.0%

5Y-2.0%

10Y+75.0%

14.12M

Total Liabilities

-18%

3Y-27.0%

5Y-37.0%

10Y-32.0%

12.87M

Total Equity

-3%

3Y-77.0%

5Y+151.0%

10Y-346.0%

CEL-SCI Corporation Funding & Solvency Profile

CVM · AMEX

Current Assets

Cash & Cash Equivalents4.74M

Net Receivables0.00

Inventory1.02M

Other Current Assets3.50K

Total Current Assets6 M

Non-Current Assets

Property, Plant & Equipment16.98M

Goodwill & Intangible Assets165.49K

Long-Term Investments0.00

Other Non-Current Assets3.79M

Total Non-Current Assets21 M

Total Assets

26.99M

Financial Health Analysis

Current Ratio

1.31x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Debt-to-Equity Ratio

1.10x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

1 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

22% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

CEL-SCI Corporation Balance Sheet

CVM • AMEX

CEL-SCI Corporation Balance Sheet	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014	Sep 2013	Sep 2012	Sep 2011	Sep 2010	Sep 2009	Sep 2008	Sep 2007	Sep 2006	Sep 2005
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	4.7M	4.1M	22.7M	36.1M	15.5M	8.4M	10.3M	2.4M	2.9M	5.7M	8.5M	41.6K	3.9M	4.3M	26.6M	33.6M	711.3K	11M	8.1M	2M
Short-Term Investments	0.0	0.0	0.0	6.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	200K	0.0	0.0	0.0
Cash & Short-Term Investments	4.7M	4.1M	22.7M	42.2M	15.5M	8.4M	10.3M	2.4M	2.9M	5.7M	8.5M	41.6K	3.9M	4.3M	26.6M	33.6M	911.3K	11M	8.1M	2M
Net Receivables	0.0	0.0	0.0	54.9K	54.9K	62.8K	118.7K	218.5K	394.5K	87.2K	81.8K	74.3K	158.6K	457.3K	0.0	5.6M	0.0	57.5K	35.6K	21.2K
Accounts Receivables	0.0	0.0	0.0	54.9K	54.9K	62.8K	118.7K	218.5K	394.5K	87.2K	81.8K	74.3K	158.6K	457.3K	0.0	5.6M	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	57.5K	35.6K	21.2K
Inventory	1M	2.2M	2M	2M	820.1K	782.4K	645.2K	672.5K	1M	1.4M	1.5M	1M	1.4M	1.6M	1.5M	399.5K	395.2K	385.7K	390.6K	0.0
Prepaids	294.1K	520.4K	762.1K	998.5K	1.3M	525K	364.6K	826.4K	981.7K	979.7K	907.5K	780.5K	1.3M	2M	298.7K	1.6M	27.2K	34.6K	526.5K	12.2K
Other Current Assets	3.5K	4.2K	0.0	0.0	0.0	0.0	0.0	150K	155K	150K	694.1K	598.7K	651.8K	703.3K	751.3K	1.6M	14.8K	14.8K	0.0	0.0
Total Current Assets	6.1M	6.9M	25.4M	45.3M	17.7M	9.8M	11.4M	4.2M	5.9M	8.8M	11.6M	2.5M	7.4M	9M	29.1M	35.6M	1.3M	11.5M	9M	2.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	17M	21M	24.7M	28.4M	20.9M	15.8M	16.2M	16.8M	226.2K	307.5K	403K	489.3K	630.9K	1M	1.3M	1.2M	1.3M	233.9K	92.1K	181.5K
Intangible Assets	165.5K	197.7K	212.2K	275.9K	313.4K	311.6K	258.1K	223.2K	256.5K	291.6K	323.6K	318.2K	384.3K	414.2K	356.1K	423.1K	587.4K	541.4K	513.2K	484.6K
Goodwill & Intangible Assets	165.5K	197.7K	212.2K	275.9K	313.4K	311.6K	258.1K	223.2K	256.5K	291.6K	323.6K	318.2K	384.3K	414.2K	356.1K	423.1K	587.4K	541.4K	513.2K	484.6K
Other Non-Current Assets	3.8M	2.4M	164.3K	1.9M	1.7M	1.7M	1.7M	1.7M	5.2M	6M	6.9M	7.5M	7.6M	8.2M	7.1M	8.8M	11.4M	8.5M	0.0	14.8K
Total Non-Current Assets	20.9M	23.6M	25.1M	30.6M	22.8M	17.8M	18.1M	18.7M	5.7M	6.6M	7.6M	8.3M	8.6M	9.6M	8.7M	10.4M	13.3M	9.2M	605.3K	680.9K
Total Assets	27M	30.5M	50.5M	75.9M	40.5M	27.6M	29.6M	22.9M	11.6M	15.4M	19.2M	10.8M	16.1M	18.6M	37.8M	46M	14.7M	20.7M	9.7M	3.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.4M	2M	1.6M	1.7M	2M	1.6M	5.7M	8.2M	3.1M	5.1M	1.2M	1.9M	792.8K	1.9M	1.5M	842.7K	427.5K	248.1K	98.1K	74.4K
Accounts Payable	1.4M	2M	1.6M	1.7M	2M	1.6M	5.7M	8.2M	3.1M	5.1M	1.2M	1.9M	592.9K	739K	1.5M	793.1K	427.5K	248.1K	98.1K	74.4K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	199.9K	1.1M	45.8K	49.5K	0.0	0.0	0.0	0.0
Accrued Expenses	566K	1.6M	842.5K	859.2K	510.5K	34.4K	205.3K	693.8K	378.7K	365.1K	547.2K	113.5K	11.5K	290.2K	223.7K	98.7K	158.7K	167.4K	149.4K	74.6K
Short Term Debt	2.2M	0.0	0.0	0.0	0.0	0.0	0.0	994.3K	0.0	1.1M	1.1M	1.1M	1.1M	5M	1.1M	1.1M	200K	0.0	0.0	0.0
Capital Lease Obligations (Current)	2.2M	2M	1.7M	698.7K	1.1M	0.0	0.0	0.0	0.0	0.0	8.5K	8.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	1.1M	958.5K	125K	126.8K	125K	125K	126.6K	126.6K	126.5K	126.5K	125K	269.5K	148.2K	158.7K	0.0	0.0	0.0
Other Current Liabilities	-1.9M	0.0	471.5K	-421.8K	-296.7K	1.3M	3.2M	835.1K	416.6K	117.1K	205.9K	268.3K	0.0	-55.4K	154.8K	35M	2.9M	812.5K	1.7M	24.2K
Total Current Liabilities	4.6M	5.6M	4.7M	3.9M	4.3M	3M	9.2M	10.8M	4M	6.9M	3.2M	3.5M	1.9M	7.2M	3.3M	37.2M	3.8M	1.2M	1.9M	173.1K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3K
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	125K	126.8K	125K	125K	126.6K	126.6K	126.5K	126.5K	125K	133.2K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	125K	125K	125K	125K	3.7M	5.8M	6.9M	2.1M	8.4M	13.7M	5.5M	445.9K	7M	2.2M	6.5M	35.1M	6.6K	4.8M	8.6M	811.2K
Total Non-Current Liabilities	9.5M	11.7M	13.7M	15.4M	16.5M	19.5M	20.4M	15.4M	8.5M	13.8M	5.6M	593.4K	7.1M	2.3M	6.7M	14.3K	6.6K	4.8M	8.6M	814.2K
Capital Lease Obligations	11.6M	13.6M	15.3M	16M	13.9M	13.5M	13.4M	13.2M	13M	9K	17.5K	29.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	14.1M	17.3M	18.4M	19.3M	20.8M	22.5M	29.6M	26.3M	12.6M	20.7M	8.8M	4.1M	9M	9.5M	10M	37.2M	3.8M	6.1M	10.6M	987.3K
SHAREHOLDERS' EQUITY
Common Stock	637.9K	474.2K	434.5K	432.1K	387.3K	352.3K	280.3K	119K	1.6M	1.1M	819K	310.3K	2.7M	2.1M	2M	1.9M	1.2M	1.2M	827K	744.9K
Additional Paid-In Capital	526.2M	499.8M	486.6M	474.3M	401.2M	358.5M	331.3M	296.3M	284.6M	269.1M	249.2M	218.6M	207.3M	194.4M	187.6M	173M	134.3M	130.1M	105.2M	100.4M
Retained Earnings	-514M	-487.1M	-454.9M	-418.2M	-381.8M	-353.7M	-331.6M	-299.8M	-285.7M	-274.2M	-239.5M	-212.2M	-203M	-187.5M	-161.8M	-166.1M	-124.7M	-116.6M	-106.9M	-99M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	401.0	339.8K	3.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	0.0
Total Stockholders' Equity	12.9M	13.2M	32.2M	56.5M	19.7M	5.1M	916.0	-3.3M	-956.1K	-5.2M	10.4M	6.7M	7M	9.1M	27.9M	8.8M	10.8M	14.7M	-930.6K	2.1M
Total Equity	12.9M	13.2M	32.2M	56.5M	19.7M	5.1M	916.0	-3.3M	-956.1K	-5.2M	10.4M	6.7M	7M	9.1M	27.9M	8.8M	10.8M	14.7M	-930.6K	2.1M
SUMMARY
Total Liabilities & Equity	27M	30.5M	50.5M	75.9M	40.5M	27.6M	29.6M	22.9M	11.6M	15.4M	19.2M	10.8M	16.1M	18.6M	37.8M	46M	14.7M	20.7M	9.7M	3.1M
Total Investments	0.0	0.0	0.0	6.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	200K	0.0	0.0	0.0
Total Debt	11.6M	13.6M	15.3M	16M	13.9M	13.5M	13.4M	14.2M	13M	1.3M	1.1M	1.1M	1.1M	5M	1.1M	1.1M	200K	0.0	0.0	3K
Net Debt	6.9M	9.4M	-7.4M	-20.1M	-1.6M	5.1M	3.1M	11.8M	10.1M	-4.5M	-7.4M	1.1M	-2.8M	738.4K	-25.5M	-32.5M	-511.3K	-11M	-8.1M	-2M
Shares Outstanding	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587	6,871,587

SEC Filings

CVM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2025 N/A	November 24, 2025	November 18, 2025	2025	View Filing
S-3 S-3 N/A	November 07, 2025	November 07, 2025		View Filing
8-K 8-K 2025 N/A	November 05, 2025	October 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 29, 2025	August 27, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 25, 2025	August 22, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 14, 2025	June 30, 2025	2025	View Filing
S-3/A S-3/A (Amended) N/A	August 05, 2025	August 05, 2025		View Filing
8-K 8-K 2025 N/A	July 14, 2025	July 11, 2025	2025	View Filing
S-3 S-3 N/A	July 03, 2025	July 03, 2025		View Filing
8-K 8-K 2025 N/A	May 23, 2025	May 21, 2025	2025	View Filing

Showing 1 to 10 of 495 filings

Related Guides

Blog Categories

Continue your CVM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.